Topic Hub
9 clinically reviewed articles, written and peer-reviewed by the HealthRX Medical Team.
Explore
Showing 9 of 9 clinical reviews.
Alendronate (Fosamax) is used off-label for glucocorticoid-induced osteoporosis. Review the clinical trial data, ACR guideline recommendations, dosing, risks, and how it compares to on-label alternatives like risedronate and denosumab.
Read clinical reviewAlendronate (Fosamax) is FDA-approved for glucocorticoid-induced osteoporosis. Review the clinical trial data, ACR guideline recommendations, dosing, and how it compares to other GIO treatments.
Read clinical reviewAlendronate (Fosamax) is used off-label for glucocorticoid-induced osteoporosis. Review the dosing protocol, clinical trial evidence, guideline recommendations, and how it compares to FDA-approved alternatives.
Read clinical reviewAlendronate (Fosamax) is FDA-approved for male osteoporosis at 10 mg daily or 70 mg weekly. Learn the dosing protocol, key trial data, monitoring plan, and how it compares to other options for men.
Read clinical reviewA detailed evidence review of alendronate (Fosamax) for male osteoporosis, covering FDA approval status, key trial data, dosing, BMD outcomes, and fracture risk reduction in men.
Read clinical reviewAlendronate (Fosamax) is FDA-approved for Paget's disease at 40 mg daily for 6 months. Learn the full dosing protocol, monitoring targets, retreatment criteria, and how it compares to zoledronic acid and risedronate.
Read clinical reviewAlendronate (Fosamax) is FDA-approved for Paget's disease of bone. This evidence summary covers dosing, trial data, guideline recommendations, and how it compares to other bisphosphonates for Paget's.
Read clinical reviewAlendronate (Fosamax) is used off-label for Paget's disease of bone. Review the clinical evidence, FDA-approved alternatives, dosing protocols, risks, and when clinicians choose this bisphosphonate over other options.
Read clinical reviewAlendronate (Fosamax) is used off-label for Paget's disease of bone. Learn about dosing, monitoring requirements, evidence quality, and how it compares to other bisphosphonates.
Read clinical review